Metagenomi (MGX) Competitors $1.91 +0.22 (+13.02%) Closing price 07/8/2025 04:00 PM EasternExtended Trading$1.94 +0.03 (+1.57%) As of 07/8/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MGX vs. MRNA, PRQR, NBTX, YMAB, IMAB, CRDF, INBX, MDWD, SOPH, and MNPRShould you be buying Metagenomi stock or one of its competitors? The main competitors of Metagenomi include Moderna (MRNA), ProQR Therapeutics (PRQR), Nanobiotix (NBTX), Y-mAbs Therapeutics (YMAB), I-Mab (IMAB), Cardiff Oncology (CRDF), Inhibrx Biosciences (INBX), MediWound (MDWD), SOPHiA GENETICS (SOPH), and Monopar Therapeutics (MNPR). These companies are all part of the "pharmaceutical products" industry. Metagenomi vs. Its Competitors Moderna ProQR Therapeutics Nanobiotix Y-mAbs Therapeutics I-Mab Cardiff Oncology Inhibrx Biosciences MediWound SOPHiA GENETICS Monopar Therapeutics Moderna (NASDAQ:MRNA) and Metagenomi (NASDAQ:MGX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations. Do insiders & institutionals have more ownership in MRNA or MGX? 75.3% of Moderna shares are owned by institutional investors. 11.0% of Moderna shares are owned by insiders. Comparatively, 17.8% of Metagenomi shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has more volatility and risk, MRNA or MGX? Moderna has a beta of 1.84, meaning that its stock price is 84% more volatile than the S&P 500. Comparatively, Metagenomi has a beta of -0.38, meaning that its stock price is 138% less volatile than the S&P 500. Do analysts recommend MRNA or MGX? Moderna currently has a consensus target price of $46.61, suggesting a potential upside of 43.24%. Metagenomi has a consensus target price of $13.00, suggesting a potential upside of 580.63%. Given Metagenomi's stronger consensus rating and higher probable upside, analysts clearly believe Metagenomi is more favorable than Moderna.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Moderna 4 Sell rating(s) 15 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.04Metagenomi 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to MRNA or MGX? In the previous week, Moderna had 19 more articles in the media than Metagenomi. MarketBeat recorded 19 mentions for Moderna and 0 mentions for Metagenomi. Moderna's average media sentiment score of 0.50 beat Metagenomi's score of 0.00 indicating that Moderna is being referred to more favorably in the media. Company Overall Sentiment Moderna Positive Metagenomi Neutral Which has better earnings and valuation, MRNA or MGX? Metagenomi has lower revenue, but higher earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioModerna$3.24B3.89-$3.56B-$8.73-3.73Metagenomi$52.29M1.37-$78.06M-$2.11-0.91 Is MRNA or MGX more profitable? Moderna has a net margin of -105.67% compared to Metagenomi's net margin of -172.21%. Moderna's return on equity of -28.69% beat Metagenomi's return on equity.Company Net Margins Return on Equity Return on Assets Moderna-105.67% -28.69% -21.94% Metagenomi -172.21%-31.21%-22.21% SummaryModerna beats Metagenomi on 10 of the 17 factors compared between the two stocks. Get Metagenomi News Delivered to You Automatically Sign up to receive the latest news and ratings for MGX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MGX vs. The Competition Export to ExcelMetricMetagenomiMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$63.17M$2.39B$5.47B$8.95BDividend YieldN/A1.80%5.25%4.06%P/E Ratio-0.918.9827.0020.10Price / Sales1.37729.50435.75120.29Price / CashN/A159.8036.8257.86Price / Book0.304.517.985.56Net Income-$78.06M$31.26M$3.16B$248.40M7 Day Performance18.63%3.57%2.40%4.67%1 Month Performance14.37%1.28%2.19%6.64%1 Year Performance-58.21%1.08%33.82%21.31% Metagenomi Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MGXMetagenomi1.7619 of 5 stars$1.91+13.0%$13.00+580.6%-56.5%$63.17M$52.29M-0.91236MRNAModerna4.3753 of 5 stars$27.59+1.6%$46.61+68.9%-72.1%$10.50B$3.24B-3.165,800PRQRProQR Therapeutics2.1054 of 5 stars$2.04flat$8.00+292.2%+32.5%$214.63M$20.46M-5.83180News CoverageNBTXNanobiotix1.6787 of 5 stars$4.73+4.4%$8.00+69.1%+2.5%$213.34M$39.18M0.00100News CoverageGap UpYMABY-mAbs Therapeutics3.2686 of 5 stars$4.51-4.0%$15.60+245.9%-62.7%$212.83M$87.68M-7.05150IMABI-Mab2.8748 of 5 stars$2.42-5.8%$6.00+147.9%+41.0%$209.87M$3.89M0.00380Gap UpCRDFCardiff Oncology1.6815 of 5 stars$3.15flat$9.88+213.5%+77.5%$209.56M$680K-3.4220Analyst ForecastINBXInhibrx Biosciences0.9825 of 5 stars$14.27-1.1%N/A+46.5%$208.89M$200K0.12166MDWDMediWound1.619 of 5 stars$19.37+0.6%$31.80+64.2%+0.1%$208.16M$20.22M-9.2780News CoverageSOPHSOPHiA GENETICS2.3357 of 5 stars$3.10+0.3%$7.00+125.8%-21.2%$206.06M$65.17M-3.10520News CoverageMNPRMonopar Therapeutics2.9043 of 5 stars$35.78+6.5%$56.50+57.9%+940.0%$205.47MN/A-10.2810News CoverageAnalyst Forecast Related Companies and Tools Related Companies Moderna Competitors ProQR Therapeutics Competitors Nanobiotix Competitors Y-mAbs Therapeutics Competitors I-Mab Competitors Cardiff Oncology Competitors Inhibrx Biosciences Competitors MediWound Competitors SOPHiA GENETICS Competitors Monopar Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MGX) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Metagenomi, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Metagenomi With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
